{"contentid": 488489, "importid": NaN, "name": "Teva dips as it reports downturn on 1st-qtr sales and earnings", "introduction": "Teva Pharmaceutical Industries yesterday reported results for the first quarter of 2021 that met earnings expectations but not sales, leading the Israeli generics giant\u00e2\u0080\u0099s shares nearly 2% lower at 3,271 shekels by close of trading on Wednesday.", "content": "<p>Teva Pharmaceutical Industries (NYSE: TEVA) yesterday reported results for the first quarter of 2021 that met earnings expectations but not sales, leading the Israeli generics giant&rsquo;s shares nearly 2% lower at 3,271 shekels by close of trading on Wednesday.</p>\n<p>Revenues were $3.98 billion, a decrease of 9% or 10% in local currency terms, compared to the first quarter of 2020. This decrease was mainly due to lower revenues from generic, OTC and respiratory products and from Copaxone (glatiramer acetate in our Europe segment. Global Copaxone sales for the quarter fell 15% to $276 million.</p>\n<p>On a generally accepted accounting principles (GAAP) basis, operating income for the quarter was $434 million, compared to $191 million in the first quarter of 2020. Non-GAAP operating income was $1.08 billion, a decrease of 13%. The decrease was mainly due to lower profit in our Europe segment.</p>\n<p>Overall, Teva earned 63 cents per diluted share excluding one-time items in the January-March period, down from 76 cents a share a year earlier. Revenue fell 9% to $3.98 billion. Analysts had forecast Teva would earn 63 cents a share ex-items on revenue of $4.02 billion, according to I/B/E/S data from Refinitiv.</p>\n<p>K&aring;re Schultz, Teva's president and chief executive, said: \"We have improved our profitability and reduced our net debt to $23.2 billion. We have also seen solid performance from our key growth drivers: the biosimilar Truxima increased its market share to 26%, Austedo [deutetrabenazine] continued its year-over-year growth, and Ajovy [fremanezumab] solidified its market share in the US and continues to expand in Europe. Based on our results and expectations for the remainder of the year, we are reaffirming our guidance.\"</p>\n<p>Teva&rsquo;s full-year 2021 forecasts is for adjusted earnings per share of $2.50 to $2.70 on sales of between $16.4 billion and $16.8 billion.</p>", "date": "2021-04-29 10:11:00", "meta_title": "Teva dips as it reports downturn on 1st-qtr sales and earnings", "meta_keywords": "Teva Pharmaceutical Indistries, Financial results, First-quarter, 2021, Copaxone, Ajovy, Austedo", "meta_description": "Teva dips as it reports downturn on 1st-qtr sales and earnings", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-29 09:02:09", "updated": "2021-04-29 10:11:14", "access": NaN, "url": "https://www.thepharmaletter.com/article/teva-dips-as-it-reports-downturn-on-1st-qtr-sales-and-earnings", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "teva-logo-big.jpg", "image2id": "teva-logo-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Generics", "therapy area_tag": "Musculoskeletal, Neurological", "topic_tag": "Financial", "geography_tag": "Israel", "company_tag": "Teva Pharmaceutical Industries", "drug_tag": "Ajovy, Austedo, Copaxone", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-29 10:11:00"}